AI Engines For more Details: Perplexity Kagi Labs You
Antiretroviral Activity: Zalcitabine is classified as a nucleoside reverse transcriptase inhibitor (NRTI). It works by interfering with the action of reverse transcriptase, an enzyme that the human immunodeficiency virus (HIV) needs to replicate its genetic material. By inhibiting reverse transcriptase, zalcitabine helps prevent the virus from multiplying in the body, thereby slowing the progression of HIV infection and reducing the risk of developing acquired immunodeficiency syndrome (AIDS).
Combination Therapy: Zalcitabine is typically used as part of combination antiretroviral therapy (ART) regimens for the treatment of HIV infection. ART involves using multiple antiretroviral medications from different drug classes to target various stages of the HIV life cycle and minimize the risk of drug resistance. Zalcitabine is often prescribed in combination with other NRTIs, non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase inhibitors to achieve optimal viral suppression and immune reconstitution in HIV-infected individuals.
Viral Load Reduction: Treatment with zalcitabine, along with other antiretroviral medications, can lead to significant reductions in HIV viral load, which is the amount of HIV RNA (genetic material) present in the blood. Lowering viral load to undetectable levels (below the limit of detection of standard laboratory assays) is a primary goal of HIV therapy. Suppressing viral replication helps preserve immune function, reduce the risk of opportunistic infections, and prolong survival in individuals living with HIV.
CD4 Cell Count Increase: Zalcitabine-containing ART regimens have been shown to increase CD4 T-cell counts in people living with HIV. CD4 T-cells are a type of white blood cell that plays a crucial role in the immune system's response to infections. HIV selectively targets and destroys CD4 T-cells, leading to immunodeficiency and increased susceptibility to opportunistic infections. By suppressing HIV replication, zalcitabine helps preserve CD4 T-cell levels and restore immune function over time.
Adverse Effects: Like other antiretroviral medications, zalcitabine may cause side effects in some individuals. Common adverse effects associated with zalcitabine therapy include gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea), peripheral neuropathy (nerve damage affecting the hands and feet), pancreatitis (inflammation of the pancreas), hepatotoxicity (liver damage), and hematologic abnormalities (e.g., anemia, neutropenia). Regular monitoring of blood counts, liver function tests, and other relevant parameters is recommended during zalcitabine treatment to detect and manage potential adverse effects.
Drug Interactions: Zalcitabine may interact with other medications, including other antiretroviral drugs, leading to changes in drug levels or effects. It is important for healthcare providers to review a patient's complete medication list and medical history before prescribing zalcitabine to minimize the risk of drug interactions and adverse effects.
Resistance Development: Like all antiretroviral medications, the long-term effectiveness of zalcitabine therapy can be limited by the development of drug-resistant HIV strains. To reduce the risk of resistance, zalcitabine should be used in combination with other potent antiretroviral agents and taken consistently as prescribed to maintain viral suppression. Resistance testing may be performed if virologic failure occurs to guide subsequent treatment decisions.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
ADHD | 0.4 | 0.4 | |
Age-Related Macular Degeneration and Glaucoma | 0 | 0.1 | 0 |
Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
Allergies | 0.7 | 0.7 | |
Allergy to milk products | 0.4 | 0.3 | 0.33 |
Alopecia (Hair Loss) | 0.3 | 0.3 | |
Alzheimer's disease | 1.4 | 0.7 | 1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.4 | 0.25 |
Ankylosing spondylitis | 1 | 0.4 | 1.5 |
Anorexia Nervosa | 0.1 | 0.1 | 0 |
Antiphospholipid syndrome (APS) | 0.7 | 0.1 | 6 |
Asthma | 0.1 | -0.1 | |
Atherosclerosis | 0.2 | 0.1 | 1 |
Atrial fibrillation | 0.4 | 0.5 | -0.25 |
Autism | 1 | 1.1 | -0.1 |
Barrett esophagus cancer | 0.2 | 0.2 | 0 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.5 | 0 | 0 |
Brain Trauma | 0.1 | -0.1 | |
Carcinoma | 0.8 | 0.2 | 3 |
Celiac Disease | 0.7 | 0.4 | 0.75 |
Cerebral Palsy | 0.2 | 0.1 | 1 |
Chronic Fatigue Syndrome | 0.8 | 0.6 | 0.33 |
Chronic Kidney Disease | 0.5 | 0 | 0 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 0 | 0 |
Chronic Urticaria (Hives) | 0.8 | 0.3 | 1.67 |
Coagulation / Micro clot triggering bacteria | 0.9 | 0.3 | 2 |
Colorectal Cancer | 2.6 | 2.6 | |
Constipation | 0.3 | 0 | 0 |
Coronary artery disease | 0.1 | 0.1 | |
COVID-19 | 1.2 | 1.4 | -0.17 |
Crohn's Disease | 2 | 0.8 | 1.5 |
cystic fibrosis | 0.5 | 0.1 | 4 |
deep vein thrombosis | 0.5 | 0.3 | 0.67 |
Depression | 2.4 | 1.2 | 1 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.3 | 1.4 | -3.67 |
Endometriosis | 1 | 1 | |
Eosinophilic Esophagitis | 0.2 | 0.2 | |
Epilepsy | 1 | 0.2 | 4 |
Fibromyalgia | 0.2 | 0.1 | 1 |
Functional constipation / chronic idiopathic constipation | 1.1 | 0.5 | 1.2 |
gallstone disease (gsd) | 0.3 | 0.3 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.2 | 1.5 |
Generalized anxiety disorder | 0.9 | 0.1 | 8 |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 0.2 | 0 | 0 |
Halitosis | 0.3 | 0.2 | 0.5 |
Hashimoto's thyroiditis | 0.1 | 0.2 | -1 |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.1 | 4 |
hyperglycemia | 0.2 | 0.2 | 0 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.6 | 0.8 | -0.33 |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 0.1 | -0.1 | |
Inflammatory Bowel Disease | 2.1 | 0.8 | 1.63 |
Insomnia | 0.3 | 0.1 | 2 |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 0.7 | 0.3 | 1.33 |
Liver Cirrhosis | 1 | 0.5 | 1 |
Long COVID | 1 | 0.6 | 0.67 |
Low bone mineral density | 0 | 0 | |
Lung Cancer | 0.2 | 0.2 | |
ME/CFS with IBS | 0.2 | 0.1 | 1 |
ME/CFS without IBS | 0.5 | 0.4 | 0.25 |
Metabolic Syndrome | 1.8 | 1.1 | 0.64 |
Mood Disorders | 2.6 | 1.2 | 1.17 |
multiple chemical sensitivity [MCS] | 1.1 | 1.1 | |
Multiple Sclerosis | 1.6 | 1.1 | 0.45 |
Multiple system atrophy (MSA) | 0 | 0 | |
Neuropathy (all types) | 0.2 | 0.2 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.1 | 3 |
Obesity | 1 | 1.8 | -0.8 |
obsessive-compulsive disorder | 1.3 | 0.2 | 5.5 |
Osteoarthritis | 0.6 | 0.6 | |
Osteoporosis | 0.3 | 0.1 | 2 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 0.8 | 1 | -0.25 |
Polycystic ovary syndrome | 0.4 | 0 | 0 |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
Psoriasis | 0.9 | 0.5 | 0.8 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 0.7 | 0.86 |
Rosacea | 0 | 0 | |
Schizophrenia | 0.4 | 0 | 0 |
scoliosis | 0.1 | -0.1 | |
Sjögren syndrome | 0.5 | 0.2 | 1.5 |
Sleep Apnea | 0.2 | 0.1 | 1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
Stress / posttraumatic stress disorder | 0.8 | 0.1 | 7 |
Systemic Lupus Erythematosus | 1.4 | 0 | 0 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 0.7 | 0.3 | 1.33 |
Type 2 Diabetes | 1.8 | 1.4 | 0.29 |
Ulcerative colitis | 1.1 | 0.4 | 1.75 |
Unhealthy Ageing | 1.5 | 0 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.